logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Clinical strategies for serious infection : A North American perspective.

    Article, Communication - En anglais

    Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, ON, CAN, 1997/09.

    In the United Sates, as in Europe, clinical strategies for serious infection are being incresingly driven by growing numbers of cephalosporin-resistant and multiresistant Gram-negative bacilli.

    In a survey of nearly 400 hospital intensive care units in Norht America, resistance rates of Klebsiella to third-generation cephalosporins increased (from 3.6 to 14.4%) between 1990 and 1993.

    Resistance rates in Enterobacter are even higher, approaching 40%. Much of this resistance, which is due mainly to production of type-1 and extended spectrum bêta-lactamases, appears to have arisen through overuse of third-generation cephalosporins and from poor hand-washing practices.

    In some American cities, a major reservoir of resistant organisms are nursing homes, where there is evidence of over-use of oral antibiotics.

    Currently, the most reliable agents available for the treatment of resistant Gram-negative pathogens are the carbapenems, imipenem/cilastatin and meropenem, and the aminoglycoside, amikacin.

    A recent clinical study of meropenem monotherapy in patients with nosocomial pneumonia showed statistically significantly better clinical and microbiologic outcome compared with a standard regimen of ceftazidime plus tobramycin.

    The enhanced in vitro activity of meropenem against a number of key organisms may have been responsible for the superior results. (...)

    Mots-clés Pascal : Bactérie Gram négatif, Résistance multiple, Milieu hospitalier, Antibiotique, Antibactérien, Céfépime, Carbapénème dérivé, bêta-Lactamase, Hydrolases, Enzyme, Cefpirome, Céphalosporine dérivé, Amérique du Nord, Amérique, Article synthèse

    Mots-clés Pascal anglais : Gram negative bacteria, Multiple resistance, Hospital environment, Antibiotic, Antibacterial agent, Cefepime, Carbapenem derivatives, bêta-Lactamase, Hydrolases, Enzyme, Cefpirome, Cephalosporin derivatives, North America, America, Review

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 98-0401066

    Code Inist : 002B02S02. Création : 25/01/1999.